Perspective: Prostate cancer susceptibility genes

Endocrinology

Volumn 143, Issue 6, 2002, Pages 2029-2040

  Simard, Jacques ^a   Dumont, Martine ^a   Soucy, Penny ^a   Labrie, Fernand ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; DNA; RIBONUCLEASE; STEROID 5ALPHA REDUCTASE;

ANDROGEN SYNTHESIS; CANCER RISK; CANCER SUSCEPTIBILITY; CONFERENCE PAPER; FAMILY HISTORY; GENE IDENTIFICATION; GENE MAPPING; GENETIC HETEROGENEITY; GENETIC LINKAGE; GENETIC MARKER; GENETIC VARIABILITY; HUMAN; INCIDENCE; INHERITANCE; MISSENSE MUTATION; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PEDIGREE; PENETRANCE; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; RISK FACTOR; SCREENING;

EID: 0036095853     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.143.6.8890     Document Type: Conference Paper

References (95)

1. International trends and patterns of prostate cancer incidence and mortality
2. Cancer of the prostate
3. Recherches clinico-statistiques et génétiques sur les néoplasies de la prostate
4. Genetics of prostate cancer: Too many loci, too few genes
5. High risk genes predisposing to prostate cancer - Do they exist?
6. Heterogeneity of genetic alterations in prostate cancer: Evidence of the complex nature of the disease
7. Familial prostate cancer and its management
8. Genetic epidemiology of prostate cancer in the Utah Mormon genealogy
9. Mendelian inheritance of familial prostate cancer
10. Family history and the risk of prostate cancer
11. Environmental and heritable factors in the causation of cancer - Analyses of cohorts of twins from Sweden, Denmark, and Finland
12. Evidence for autosomal dominant inheritance of prostate cancer
13. Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus
14. The impact of family history on early detection of prostate cancer
15. Evidence of an X-linked or recessive genetic component to prostate cancer risk
16. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genomewide search
17. Linkage of prostate cancer susceptibility loci to chromosome 1
18. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43
19. Evidence for a prostate cancer susceptibility locus on the X chromosome
20. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36
21. Evidence for a prostate cancer-susceptibility locus on chromosome 20
22. A candidate prostate cancer susceptibility gene at chromosome 17p
23. Linkage and association studies of prostate cancer susceptibility: Evidence for linkage at 8p22-23
24. Molecular genetics of prostate cancer
25. Prostate cancer susceptibility locus HPC1 in Utah high-risk pedigrees
26. Linkage analysis of chromosome 1q markers in 136 prostate cancer families
27. Linkage analysis of 150 high-risk prostate cancer families at 1q24-25
28. A genetic epidemiological study of hereditary prostate cancer (HPC) in Finland: Frequent HPCX linkage in families with late-onset disease
29. Clinical characteristics of prostate cancer in an analysis of linkage to four putative susceptibility loci
30. PCAP is the major known prostate cancer predisposing locus in families from south and west Europe
31. Model-free linkage analysis with covariates confirms linkage of prostate cancer to chromosomes 1 and 4
32. Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer
33. Suggestive evidence for a site specific prostate cancer gene on chromosome 1p36
34. Evidence for a prostate cancer linkage to chromosome 20 in 159 hereditary prostate cancer families
35. Analysis of the prostate cancer-susceptibility locus HPC20 in 172 families affected by prostate cancer
36. Linkage analysis of 153 prostate cancer families over a 30-cM region containing the putative susceptibility locus HPCX
37. Genetic linkage analysis of prostate cancer families to Xq27-28
38. Analysis of HPC1, HPCX, and PCaP in Icelandic hereditary prostate cancer
39. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13- p22
40. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
41. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13
42. Association of HPC2/ELAC2 genotypes and prostate cancer
43. Polymorphisms in the prostate cancer susceptibility gene HPC2/ELAC2 in multiplex families and healthy controls
44. Role of HPC2/ELAC2 in hereditary prostate cancer
45. ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer
46. Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer
47. Germline mutations In the ribonuclease L gene in families showing linkage with HPC1
48. Breast cancer risks in relatives of male breast cancer patients
49. Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer
50. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium
51. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium
52. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes
53. BRCA2 mutation in Icelandic prostate cancer patients
54. Population-based study of risk of breast cancer in carriers of BRCA2 mutation
55. Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer
56. The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer
57. No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer
58. Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men
59. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators
60. BRCA2 mutation in a family with hereditary prostate cancer
61. BRCA1 and BRCA2 have a limited role in familial prostate cancer
62. Androgen metabolism and prostate cancer: Establishing a model of genetic susceptibility
63. Molecular epidemiology of hormonemetabolic loci in prostate cancer
64. The androgen receptor gene and its influence on the development and progression of prostate cancer
65. Androgen receptor signaling in androgen-refractory prostate cancer
66. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer
67. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer
68. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function
69. Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: Possible pathogenetic relevance for the (CAG)n-expanded neuronopathies
70. Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: Specificity in prostate and non-prostate cell lines
71. Polymorphic repeats in the androgen receptor gene in high-risk sibships
72. Genetic linkage mapping of the human steroid 5α-reductase type 2 gene (SRD5A2) close to D2S352 on chromosome region 2p23->p22
73. DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: Its role during aging
74. 5α-reductase activity and risk of prostate cancer among Japanese and US white and black males
75. Genetic variability of the human SRD5A2 gene: Implications for prostate cancer risk
76. A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase
77. Biochemical and pharmacogenetic dissection of human steroid 5α-reductase type II
78. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA
79. Association of SRD5A2 genotype and pathological characteristics of prostate tumors
80. Evidence for an association between the SRD5A2 (type II steroid 5α-reductase) locus and prostate cancer in Italian patients
81. A missense substitution A49T in the steroid 5α-reductase gene (SRD5A2) is not associated with prostate cancer in Finland
82. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: A population-based case-control study
83. CYP17 and breast cancer risk: The polymorphism in the 5′ flanking area of the gene does not influence binding to Sp-1
84. The T/c allelic polymorphism at nucleotide +27 of the human Cyp17 gene is not associated with altered transcriptional activity
85. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2)
86. A polymorphism in the CYP17 gene is associated with prostate cancer risk
87. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5α-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population
88. Prostate cancer associated with CYP17 genotype
89. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect
90. Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer
91. Regression models for linkage heterogeneity applied to familial prostate cancer
92. Gene expression profiling predicts clinical outcome of breast cancer
93. Comprehensive analysis of photoreceptor gene expression and the identification of candidate retinal disease genes